Literature DB >> 8989780

HPV infection and disease in men.

J M Palefsky1, R Barrasso.   

Abstract

Penile HPV infection and disease are very common in sexually active men, and may be manifest in many forms. Treatment of clinically detectable lesions is advisable not only to relieve symptoms but also to prevent the spread of HPV infection to new sexual partners. Treatment of subclinical disease is more controversial but also may be advisable in some cases given the evidence that these lesions may also harbor infectious virus. In addition, subclinical disease may demonstrate intraepithelial neoplasia, which if left untreated may progress to invasive cancer in a small number of cases. Anal HPV infection and ASIL are very common in high-risk homosexual and bisexual men, particularly among those who are HIV positive. Parallels with cervical HPV infection and disease suggest that anal HSIL may be precancerous, and indeed anal cancer may be as common or more common in this high-risk group as cervical cancer is in women. Further studies are needed to elucidate the natural history of ASIL, the role of immunosuppression in progression to invasive cancer, optimal diagnostic methods, and optimal treatment regimens. Like cervical cancer, anal cancer may be a preventable disease, and implementation of a well-targeted screening program similar to that in place for cervical disease should be considered in the future when appropriate supporting data become available.

Entities:  

Mesh:

Year:  1996        PMID: 8989780     DOI: 10.1016/s0889-8545(05)70281-3

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  7 in total

1.  Penile intraepithelial neoplasia--a veiled lesion in genitourinary medicine.

Authors:  H Jaleel; N Narouz; A A Wade; P S Allan
Journal:  Sex Transm Infect       Date:  1999-12       Impact factor: 3.519

Review 2.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

3.  Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Authors:  Madhur K Garg; Fengmin Zhao; Joseph A Sparano; Joel Palefsky; Richard Whittington; Edith P Mitchell; Mary F Mulcahy; Karin I Armstrong; Nassim H Nabbout; Shalom Kalnicki; Bassel F El-Rayes; Adedayo A Onitilo; Daniel J Moriarty; Thomas J Fitzgerald; Al B Benson
Journal:  J Clin Oncol       Date:  2017-01-09       Impact factor: 44.544

4.  Knowledge and beliefs regarding human papillomavirus among college nursing students at a minority-serving institution.

Authors:  Geri L Schmotzer; Kerryn W Reding
Journal:  J Community Health       Date:  2013-12

5.  Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.

Authors:  Joseph A Sparano; Jeannette Y Lee; Joel Palefsky; David H Henry; William Wachsman; Lakshmi Rajdev; David Aboulafia; Lee Ratner; Thomas J Fitzgerald; Lisa Kachnic; Ronald Mitsuyasu
Journal:  J Clin Oncol       Date:  2016-12-12       Impact factor: 44.544

6.  Association between human papillomavirus in men and their sexual partners and uterine cervical intraepithelial neoplasia.

Authors:  José Guzmán-Esquivel; Alicia Martínez-Contreras; Mario Ramírez-Flores; Lilia M Jiménez Ceja; Ivan Delgado-Enciso; Sandra Martínez-Garza; Luz M Baltazar Rodríguez
Journal:  Int Urol Nephrol       Date:  2008-07-22       Impact factor: 2.370

7.  A 12-year retrospective evaluation of anal pre-cancerous lesions and cancer in people living with HIV-1 infection in the Southeastern U.S.

Authors:  Yuanfan Ye; Greer A Burkholder; Amrita Mukherjee; Daniel Chu; Anju Bansal; Staci L Sudenga; Anna Junkins; Sameer Al Diffalha; Michael S Saag; Sadeep Shrestha
Journal:  Infect Agent Cancer       Date:  2021-02-17       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.